其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Syrosingopine CAS Registry Number: 84-36-6 乙酯利血平

CAS Name: 18-[[4-[(Ethoxycarbonyl)oxy]-3,5-dimethoxybenzoyl]oxy]-11,17-dimethoxyyohimban-16-carboxylic acid methyl ester
Additional Names: methyl carbethoxysyringoyl reserpate; carbethoxysyring...
Literature References: Prepn: Lucas et al., J. Am. Chem. Soc. 81, 1928 (1959); US 2813871 (1957 to Ciba).

Mephenoxalone CAS Registry Number: 70-07-5 美芬诺酮

CAS Name: 5-[(2-Methoxyphenoxy)methyl]-2-oxazolidinone
Additional Names: 5-(o-methoxyphenoxymethyl)-2-oxazolidinone; metoxadone; methoxydon(e); methoxadoneTrademarks: Dorsiflex (Drossapharm); C...
Literature References: Prepn: Lunsford et al., J. Am. Chem. Soc. 82, 1166 (1960); Lunsford, US 2895960 (1959 to A. H. Robins). Toxicity data: E. I. Goldenthal, Toxicol. Appl. Pharmacol. 18, 185 (1971). Determn in pharmaceutical formulations: N. Erk, J. Pharm. Biomed. Anal. 21, 429 (1999).

Metaxalone CAS Registry Number: 1665-48-1 美他沙酮

CAS Name: 5-(3,5-Dimethylphenoxymethyl)-2-oxazolidinoneTrademarks: Skelaxin (Robins)
Percent Composition: C 65.14%, H 6.83%, N 6.33%, O 21.69%
Literature References: Prepn: Lunsford et al., J. Am. Chem. Soc. 82, 1166 (1960); Lunsford, US 3062827 (1962 to A. H. Robins).

Guaiacol Benzoate CAS Registry Number: 531-37-3 苯甲酸2-甲氧基苯酯

CAS Name: 2-Methoxyphenol benzoate
Additional Names: benzoylguaiacol
Trademarks: Benzosol
Percent Composition: C 73.67%, H 5.30%, O 21.03%
Literature References: Prepn: Lynch, Moore, Can. J. Chem. 40, 1461 (1962).

Cyheptamide CAS Registry Number: 7199-29-3 环庚米特

CAS Name: 10,11-Dihydro-5H-dibenzo[a,d]cycloheptene-5-carboxamide
Additional Names: dibenzo[a,d][1,4]cycloheptadiene-5-carboxamidePercent Composition: C 80.98%, H 6.37%, N 5.90%, O 6.74%
Literature References: Prepn: M. A. Davis et al., FR 1355829 (1964 to Ayerst, McKenna Harrison); M. A. Davis, S. O. Winthrop, US 3242212 (1966 to Am. Home Prods.). Prepn and anticonvulsant activity: M. A. Davis et al., J. Med. Chem. 7, 88 (1964). Physical characteristics: H. J. Doorenbos et al., Pharm. Weekbl. 104, 732 (1969). Pharmacology: A. B. H. Funcke et al., Arch. Int. Pharmacodyn. 187, 174 (1970). Toxicological studies: C. J. van Eeken et al., ibid. 188, 79 (1970). Metabolism in animals and man: M. Kraml et al., Biochem. Pharmacol. 20, 2327 (1971). Comparison of potency with other anticonvulsants: G. L. Jones et al., J. Pharm. Sci. 70, 618 (1981). Elucidation of structure by x-ray diffraction, mode of action: P. W. Codding et al., J. Med. Chem. 27, 649 (1984).

Ritipenem CAS Registry Number: 84845-57-8 利替培南

CAS Name: (5R,6S)-3-[[(Aminocarbonyl)oxy]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
Additional Names: (5R,6S,8R)-6a-hydroxyethyl-2-carbamoyloxy...
Literature References: Prepn: M. Alpegiani et al., DE 3245270; M. Foglio et al., US 4482565 (1983, 1984 both to Carlo Erba). Synthesis: G. Franceschi et al., J. Antibiot. 36, 938 (1983). Total synthesis: W. Cabri et al., Tetrahedron Lett. 34, 3491 (1993). Toxicity study: M. Brughera et al., J. Antimicrob. Chemother. 23, Suppl. C, 129 (1989). Series of articles on synthesis, in vitro activity, metabolism: ibid., 1-204 (1989). Clinical pharmacokinetics of acid and ester forms: S. R. Norrby et al., ibid. 25, 371 (1990); A. M. Lovering et al., ibid. 29, 179 (1992). HPLC determn in serum and urine: R. Mendez et al., J. Chromatogr. 579, 115 (1992).

Idrocilamide CAS Registry Number: 6961-46-2 羟乙桂胺

CAS Name: N-(2-Hydroxyethyl)-3-phenyl-2-propenamide
Additional Names: N-(2-hydroxyethyl)cinnamamideTrademarks: Brolitène (Lab. Medicia); Srilane (Medicia)
Percent Composition: C 69.09%, H 6....
Literature References: Prepn: M. Bayssat et al., DE 2015447; eidem, US 3659014 (1970, 1972 to LIPHA); Chim. Ther. 8, 202 (1973). Pharmacology: Grand et al., Eur. J. Med. Chem. 9, 205 (1974). Metabolism: Belleville et al., Therapie 29, 829 (1974).

Cefuroxime CAS Registry Number: 55268-75-2 头孢呋肟

CAS Name: (6R,7R)-3-[[(Aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-furanyl(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Additional Names: (6R,7R)-3-carbamoylo...
Literature References: Prepn: M. C. Cook et al., DE 2439880; eidem, US 3974153 (1973, 1976 both to Glaxo). Prepn of the 1-acetoxyethyl ester: M. Gregson, B. Sykes, DE 2706413; eidem, US 4267320 (1977, 1981 both to Glaxo). In vitro studies: C. H. O'Callaghan et al., Antimicrob. Agents Chemother. 9, 511 (1976); R. N. Jones et al., ibid. 12, 47 (1977). In vitro antibacterial activity, human pharmacokinetics: C. H. O'Callaghan et al., J. Antibiot. 29, 29 (1976). Pharmacology: H. Freiesleben et al., Proc. 10th Int. Congr. Chemother., Zürich, 1977 (Am. Soc. for Microbiol., Washington, 1978) II, pp 873-874. Pharmacokinetics: P. E. Gower, ibid. 877-878; J. Kosmidis et al., ibid. 875-876. Clinical studies: P. F. Wood et al., ibid. 1042-1044; R. Norrby et al., J. Antimicrob. Chemother. 3, 355 (1977). Review of antibacterial activity, pharmacology and therapeutic efficacy: R. N. Brogden et al., Drugs 17, 233-266 (1979). Comprehensive description: T. J. Wozniak, J. R. Hicks, Anal. Profiles Drug Subs. 20, 209-236 (1991).

Anthiolimine CAS Registry Number: 305-97-5 安锑锂明

CAS Name: Mercaptobutanedioic acid antimony(3+) lithium salt (3:1:6)
Additional Names: 2,2',2''-[stibilidynetris(thio)]trisbutanedioic acid hexalithium salt; mercaptosuccinic acid antimonate (I...
Literature References: Prepn: M. Delépine, P. Gailliot, US 2060181 (1936 to Rhône-Poulenc). Antitrypanosomal activity: N. Ercoli et al., Chemotherapy (Basel) 26, 254 (1980). Therapeutic use in buffaloes: R. K. Gupta, S. P. Pachauri, Agric. Sci. Dig. 2, 65 (1982); V. Kumar et al., J. Vet. Parasitol. 3, 125 (1989). HPLC determn in biological fluids: N. A. El-Rabbat et al., Talanta 37, 951 (1990); titrimetric determn: F. Belal et al., Microchem. J. 44, 296 (1991).

TEMED CAS Registry Number: 110-18-9 四甲基乙二胺(TEMED)

CAS Name: N,N,N',N'-Tetramethyl-1,2-ethanediamine
Additional Names: TMEDA
Percent Composition: C 62.02%, H 13.88%, N 24.11%
Literature References: Prepn: M. Freund, H. Michaels, Ber. 30, 1374 (1897); W. Hanhart, C. K. Ingold, J. Chem. Soc. 1927, 997. Base strength: L. Spialter, R. W. Moshier, J. Am. Chem. Soc. 79, 5955 (1957). Effect on kinetics of gel polymerization: Y. Pegon, C. Quincy, J. Chromatogr. 100, 11 (1974); on gel pore size: H. Tamagawa et al., Polymer 41, 7201 (2000). Use as initiatior in electrophoresis: B. J. Bassam, S. Bentley, BioTechniques 19, 568 (1995); as chelator in biological redox systems: H. C. Chang, J. A. Bumpus, Proc. Natl. Sci. Counc. ROC(B) 25, 26 (2001); as solvent in RPLC: L. Palego et al., Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25, 519 (2001); in capillary isoelectric focusing: D. Mohan, C. S. Lee, J. Chromatogr. A 979, 271 (2002).